ENBUMYST (Bumetanide) Patent Expiration, LOE Window & CMS Spending

ENBUMYST (Bumetanide) by Corstasis Therapeutics: FDA Orange Book core substance LOE 2045-05-14, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $1,197 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCorstasis Therapeutics
FDA Application & PathwayN219500 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2045-05-14
Last Listed Patent or Exclusivity Date2045-05-14
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,197 intro WAC)